Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024:104:139-179.
doi: 10.1007/978-3-031-58843-3_8.

Macromolecular Interactions of Lipoprotein Lipase (LPL)

Affiliations
Review

Macromolecular Interactions of Lipoprotein Lipase (LPL)

Anna Wheless et al. Subcell Biochem. 2024.

Abstract

Lipoprotein lipase (LPL) is a critical enzyme in humans that provides fuel to peripheral tissues. LPL hydrolyzes triglycerides from the cores of lipoproteins that are circulating in plasma and interacts with receptors to mediate lipoprotein uptake, thus directing lipid distribution via catalytic and non-catalytic functions. Functional losses in LPL or any of its myriad of regulators alter lipid homeostasis and potentially affect the risk of developing cardiovascular disease-either increasing or decreasing the risk depending on the mutated protein. The extensive LPL regulatory network tunes LPL activity to allocate fatty acids according to the energetic needs of the organism and thus is nutritionally responsive and tissue dependent. Multiple pharmaceuticals in development manipulate or mimic these regulators, demonstrating their translational importance. Another facet of LPL biology is that the oligomeric state of the enzyme is also central to its regulation. Recent structural studies have solidified the idea that LPL is regulated not only by interactions with other binding partners but also by self-associations. Here, we review the complexities of the protein-protein and protein-lipid interactions that govern LPL structure and function.

Keywords: Angiopoietin-like protein; Apolipoprotein; CryoEM; Helix; Heparin; Lipase maturation factor 1; Lipoprotein lipase; Syndecan-1; Triglyceride.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Aggerbeck LP, Wetterau JR, Weisgraber KH, Wu CS, Lindgren FT (1988) Human apolipoprotein E3 in aqueous solution. II. Properties of the amino- and carboxyl-terminal domains. J Biol Chem 263(13):6249–6258 - DOI - PubMed
    1. Allan CM, Larsson M, Jung RS, Ploug M, Bensadoun A, Beigneux AP, Fong LG, Young SG (2017) Mobility of “HSPG-bound” LPL explains how LPL is able to reach GPIHBP1 on capillaries. J Lipid Res 58(1):216–225. https://doi.org/10.1194/jlr.M072520 - DOI - PubMed
    1. Anderson NG, Fawcett B (1950) An antichylomicronemic substance produced by heparin injection. Proc Soc Exp Biol Med 74(4):768–771. https://doi.org/10.3181/00379727-74-18042 - DOI - PubMed
    1. Ando Y, Shimizugawa T, Takeshita S, Ono M, Shimamura M, Koishi R, Furukawa H (2003) A decreased expression of angiopoietin-like 3 is protective against atherosclerosis in apoE-deficient mice. J Lipid Res 44(6):1216–1223. https://doi.org/10.1194/jlr.M300031-JLR200 - DOI - PubMed
    1. Anfinsen CB, Boyle E, Brown RK (1952) The role of heparin in lipoprotein metabolism. Science 115(2996):583–586. https://doi.org/10.1126/science.115.2996.583 - DOI - PubMed

LinkOut - more resources